- Home
- CYRX vs AUTL Comparison
CYRX vs AUTL Comparison
Compare CYRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 431.2M |
| IPO Year | 2008 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CYRX | AUTL |
|---|---|---|
| Price | $8.05 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $12.94 | $8.50 |
| AVG Volume (30 Days) | 341.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 28.33 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | $10,120,000.00 |
| Revenue This Year | $9.71 | $670.78 |
| Revenue Next Year | $9.56 | $80.13 |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $4.63 | $1.11 |
| 52 Week High | $11.45 | $2.70 |
Technical Indicators
Market Signals| Indicator | CYRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 44.77 |
| Support Level | $6.57 | $1.27 |
| Resistance Level | $8.45 | $1.52 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 25.71 | 18.27 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.